Go Deep
CG Oncology, Inc.
CG Oncology, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,437 | -23.2 | 5.38 | 0.01 | 5,942.58 |
| Oct 2026 | 17,496 | -23.0 | 5.33 | 0.01 | 5,871.55 |
| Oct 2026 | 17,493 | -23.2 | 5.33 | 0.01 | 5,874.29 |
| Oct 2026 | 17,705 | -22.2 | 5.16 | 0.01 | 5,668.69 |
| Oct 2026 | 17,693 | -22.3 | 5.16 | 0.01 | 5,685.19 |
| Oct 2026 | 17,486 | -23.0 | 5.33 | 0.01 | 5,871.98 |
| Oct 2026 | 17,454 | -23.1 | 5.36 | 0.01 | 5,886.79 |
| Oct 2026 | 17,422 | -23.2 | 5.39 | 0.01 | 5,903.20 |
CG Oncology, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,157,000.0 | 1,083,000.0 | 2,322,000.0 | 1,666,000.0 |
| Net Profit | -79,056,000.0 | -60,202,000.0 | -41,309,000.0 | -43,808,000.0 |
| EPS | -0.9 | -0.7 | — | -0.6 |
CG Oncology, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 4,040,000.0 | 1,139,000.0 | 204,000.0 | 191,000.0 | — |
| Net Profit | -160,995,000.0 | -88,039,000.0 | -48,607,000.0 | -35,443,000.0 | — |
| EPS | -2.1 | -1.4 | -15.7 | -11.7 | — |
CG Oncology, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 791,592,000.0 | 754,797,000.0 | 199,301,000.0 | 147,747,000.0 | — |
| Total Liabilities | 38,990,000.0 | 21,420,000.0 | 14,511,000.0 | 22,570,000.0 | — |
| Total Equity | 752,602,000.0 | 733,377,000.0 | 184,790,000.0 | 125,177,000.0 | — |
Owes vs Owns
CG Oncology, Inc. owed $0.05 for every $1 it owned in Jun 2026, down from $0.15 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.05× | 0.05× | 0.03× | 0.07× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
CG Oncology, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.8%Fixed assets (tangible) 2.5%Intangible assets 1.4%Other assets 2.1%
How it's funded — Dec 2025
Payables 0.7%Other liabilities 3.7%Shareholders' equity 95.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 742.2 | 742.0 | 187.7 | 143.5 |
| Receivables | 0.7 | 0.0 | 0.1 | 0.3 |
| Inventory | 1.6 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 19.6 | 0.5 | 0.5 | 0.5 |
| Intangible assets | 10.9 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 16.7 | 12.3 | 11.0 | 3.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.9 | 0.2 | 0.2 | 9.0 |
| Long-term debt | 3.0 | 0.1 | 0.2 | 6.5 |
| Payables | 5.7 | 6.5 | 3.2 | 1.0 |
| Other liabilities | 29.4 | 14.7 | 10.8 | 6.1 |
| Shareholders' equity | 752.6 | 733.4 | 184.8 | 125.2 |
| Net tangible assets | 741.7 | 733.4 | 184.8 | 125.2 |
CG Oncology, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -132,346,000.0 | -78,713,000.0 | -45,679,000.0 | -29,804,000.0 | — |
| Investing Activities | -245,822,000.0 | -300,764,000.0 | -121,195,000.0 | -55,352,000.0 | — |
| Financing Activities | 153,590,000.0 | 628,279,000.0 | 86,997,000.0 | 119,692,000.0 | — |